Your browser is no longer supported. Please, upgrade your browser.
CNSP CNS Pharmaceuticals, Inc. monthly Stock Chart
CNS Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own0.90% Shs Outstand16.48M Perf Week11.63%
Market Cap38.18M Forward P/E- EPS next Y-0.49 Insider Trans- Shs Float6.58M Perf Month37.14%
Income-9.00M PEG- EPS next Q-0.09 Inst Own0.70% Short Float1.14% Perf Quarter1.27%
Sales- P/S- EPS this Y39.60% Inst Trans9.86% Short Ratio1.09 Perf Half Y-15.79%
Book/sh0.15 P/B16.00 EPS next Y-2.10% ROA-170.30% Target Price- Perf Year-
Cash/sh0.08 P/C29.37 EPS next 5Y- ROE-182.60% 52W Range1.26 - 5.62 Perf YTD-39.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.30% Beta-
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low90.75% ATR0.17
Employees3 Current Ratio4.90 Sales Q/Q- Oper. Margin- RSI (14)67.34 Volatility8.62% 9.69%
OptionableNo Debt/Eq0.00 EPS Q/Q-134.30% Profit Margin- Rel Volume0.48 Prev Close2.38
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume69.29K Price2.40
Recom1.50 SMA2016.67% SMA5024.42% SMA200-4.28% Volume33,544 Change1.05%
Aug-24-20Initiated Ladenburg Thalmann Buy $11
Nov-24-20 08:00AM  
Nov-19-20 08:00AM  
Nov-18-20 08:00AM  
Nov-17-20 08:00AM  
Nov-12-20 08:00AM  
Oct-29-20 08:00AM  
Oct-12-20 08:00AM  
Oct-09-20 08:00AM  
Oct-01-20 08:00AM  
Sep-24-20 08:00AM  
Sep-17-20 08:00AM  
Sep-11-20 08:00AM  
Sep-10-20 09:00AM  
Sep-03-20 08:00AM  
Aug-27-20 08:00AM  
Aug-25-20 08:39AM  
Aug-20-20 08:00AM  
Aug-11-20 08:00AM  
Jul-22-20 08:00AM  
Jul-15-20 08:00AM  
Jul-08-20 08:00AM  
Jun-30-20 08:00AM  
Jun-29-20 08:35AM  
Jun-23-20 08:49AM  
Jun-11-20 08:00AM  
Jun-09-20 08:00AM  
May-28-20 08:00AM  
May-27-20 06:00PM  
May-18-20 08:48AM  
May-11-20 08:00AM  
May-08-20 05:10PM  
May-04-20 07:12PM  
Apr-30-20 08:00AM  
Apr-24-20 03:05AM  
CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Downs ChristopherChief Financial OfficerAug 24Buy2.04142,000289,680142,000Aug 25 07:11 PM